The IMI recognises that it is a difficult time for all, and many members have been impacted during COVID-19. Over the past few months, the group has re-focused efforts to ensure that we can deliver planned consensus reports early 2021. The IMI consensus group, a group of key clinical researchers, scientists, and eye care practitioners continues their efforts to advance myopia research, education and advocacy.
The issue of chronic eye health issues and their long-term impact on vision impairment and blindness continues to keep driving IMI’s mission; to prevent future vision impairment from high myopia related complications with evidence-based management of myopia.
The International Myopia Institute had a recent online meeting to plan for the publication of new white papers. These new white papers, which continue from the initial papers published in 2019 in the high impact, peer reviewed journal Investigative Ophthalmology and Visual Science (IOVS), serve to bring consensus to areas not previously addressed.
The current white papers and clinical summaries are available here.
The taskforces have been set up to bring consensus to the following areas.
The International Myopia Institute was founded by BHVI and is supported through ongoing donations from industry partners; Carl Zeiss Vision, CooperVision, Essilor, Alcon and Vision Impact Institute.